JP2017536399A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536399A5 JP2017536399A5 JP2017529629A JP2017529629A JP2017536399A5 JP 2017536399 A5 JP2017536399 A5 JP 2017536399A5 JP 2017529629 A JP2017529629 A JP 2017529629A JP 2017529629 A JP2017529629 A JP 2017529629A JP 2017536399 A5 JP2017536399 A5 JP 2017536399A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halo
- group
- disorder
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims 35
- 125000001475 halogen functional group Chemical group 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 201000000980 schizophrenia Diseases 0.000 claims 5
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 206010020765 hypersomnia Diseases 0.000 claims 4
- 208000020016 psychiatric disease Diseases 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- 208000020401 Depressive disease Diseases 0.000 claims 3
- 150000001204 N-oxides Chemical class 0.000 claims 3
- 208000027626 Neurocognitive disease Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 208000000044 Amnesia Diseases 0.000 claims 2
- 208000031091 Amnestic disease Diseases 0.000 claims 2
- 206010012218 Delirium Diseases 0.000 claims 2
- 208000037490 Medically Unexplained Symptoms Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims 2
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 2
- 230000006986 amnesia Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 238000001228 spectrum Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- -1 1H-pyrazolyl Chemical group 0.000 claims 1
- GLQXAHBYDJPCHG-UHFFFAOYSA-N 6,7-dihydro-5h-pyrazolo[1,5-a]pyrazin-4-one Chemical group O=C1NCCN2N=CC=C12 GLQXAHBYDJPCHG-UHFFFAOYSA-N 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- APLZLUYWLINBOZ-UHFFFAOYSA-N 5-bromo-2-methyl-1h-imidazole Chemical compound CC1=NC=C(Br)N1 APLZLUYWLINBOZ-UHFFFAOYSA-N 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196082.3 | 2014-12-03 | ||
| EP14196082 | 2014-12-03 | ||
| PCT/EP2015/078285 WO2016087487A1 (en) | 2014-12-03 | 2015-12-02 | 6,7-DIHYDROPYRAZOLO[1,5-α]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536399A JP2017536399A (ja) | 2017-12-07 |
| JP2017536399A5 true JP2017536399A5 (enExample) | 2019-01-24 |
| JP6689856B2 JP6689856B2 (ja) | 2020-04-28 |
Family
ID=52002818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529629A Expired - Fee Related JP6689856B2 (ja) | 2014-12-03 | 2015-12-02 | ６，７−ジヒドロピラゾロ［１，５−ａ］ピラジン−４（５Ｈ）−オン化合物およびＭＧＬＵＲ２受容体の負のアロステリック調節因子としてのそれらの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10072014B2 (enExample) |
| EP (1) | EP3227295B1 (enExample) |
| JP (1) | JP6689856B2 (enExample) |
| CN (1) | CN107001375B (enExample) |
| AU (1) | AU2015357167B2 (enExample) |
| CA (1) | CA2967153A1 (enExample) |
| ES (1) | ES2727379T3 (enExample) |
| RU (1) | RU2711382C2 (enExample) |
| WO (1) | WO2016087487A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20150177B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| JOP20150179B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| JP6861154B2 (ja) | 2014-12-03 | 2021-04-21 | ヤンセン ファーマシューティカ エヌ．ベー． | 放射標識されたｍＧｌｕＲ２ ＰＥＴリガンド |
| CN107001375B (zh) | 2014-12-03 | 2020-06-09 | 詹森药业有限公司 | 6,7-二氢吡唑并[1,5-a]吡嗪-4(5H)-酮化合物及其作为MGLUR2受体的负向别构调节剂的用途 |
| US11045562B2 (en) | 2015-12-18 | 2021-06-29 | Janssen Pharmaceutica Nv | Radiolabelled mGluR2/3 PET ligands |
| HUE050665T2 (hu) | 2015-12-18 | 2020-12-28 | Janssen Pharmaceutica Nv | Radiojelzett MGLUR2/3 PET ligandumok |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| MX2019008230A (es) | 2017-01-10 | 2019-10-24 | Bayer Ag | Derivados heterociclicos como agentes de control de plagas. |
| JP7101177B2 (ja) | 2017-01-10 | 2022-07-14 | バイエル・アクチエンゲゼルシヤフト | 有害生物防除剤としてのヘテロサイクレン誘導体 |
| MY201041A (en) | 2017-11-24 | 2024-01-31 | Sumitomo Pharma Co Ltd | Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group ii metabotropic glutamate receptor |
| JP7266010B2 (ja) | 2019-05-30 | 2023-04-27 | 住友ファーマ株式会社 | ６，７－ジヒドロピラゾロ［１，５－ａ］ピラジノン誘導体又はその塩を含有する医薬 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0756200B1 (en) | 1995-07-26 | 1999-11-10 | Konica Corporation | Silver halide color photographic light-sensitive material |
| US6482821B2 (en) | 1996-12-20 | 2002-11-19 | Hoechst Aktiengellschaft | Vitronectin receptor antagonists, their preparation and their use |
| DE19653647A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
| US6754375B1 (en) | 1999-07-16 | 2004-06-22 | Packard Bioscience Company | Method and system for interactively developing at least one grid pattern and computer-readable storage medium having a program for executing the method |
| US6831074B2 (en) | 2001-03-16 | 2004-12-14 | Pfizer Inc | Pharmaceutically active compounds |
| US20030114448A1 (en) | 2001-05-31 | 2003-06-19 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| WO2005061507A1 (en) | 2003-12-16 | 2005-07-07 | Pfizer Products Inc. | Bicyclic pyrazol-4-one cannabinoid receptor ligands and uses thereof |
| WO2006030847A1 (ja) | 2004-09-17 | 2006-03-23 | Dainippon Sumitomo Pharma Co., Ltd. | 新規二環性ピラゾール誘導体 |
| DE102004054665A1 (de) | 2004-11-12 | 2006-05-18 | Bayer Cropscience Gmbh | Substituierte bi- und tricyclische Pyrazol-Derivate Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| US7998959B2 (en) | 2006-01-12 | 2011-08-16 | Incyte Corporation | Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
| JP5523829B2 (ja) | 2006-06-29 | 2014-06-18 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| WO2008141249A1 (en) | 2007-05-10 | 2008-11-20 | Acadia Pharmaceuticals Inc. | Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors |
| EP2085390A1 (en) | 2008-01-31 | 2009-08-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors |
| US9446995B2 (en) | 2012-05-21 | 2016-09-20 | Illinois Institute Of Technology | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions |
| AU2009228765B2 (en) | 2008-03-24 | 2012-05-31 | Novartis Ag | Arylsulfonamide-based matrix metalloprotease inhibitors |
| WO2009130232A1 (en) | 2008-04-24 | 2009-10-29 | Glaxo Group Limited | Pyrazolo [1, 5 -a] pyrazine derivatives as antagonists of v1b receptors |
| US20110230472A1 (en) | 2008-08-29 | 2011-09-22 | Shionogi & Co., Ltd. | Ring-fused azole derivative having pi3k-inhibiting activity |
| SG176021A1 (en) | 2009-05-12 | 2011-12-29 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| CN103108871B (zh) | 2010-09-16 | 2014-09-10 | 诺华股份有限公司 | 17α-羟化酶/C17,20-裂合酶抑制剂 |
| EP2638040A1 (en) | 2010-11-08 | 2013-09-18 | Janssen Pharmaceuticals, Inc. | RADIOLABELLED mGLuR2 PET LIGANDS |
| WO2012083224A1 (en) * | 2010-12-17 | 2012-06-21 | Vanderbilt University | Bicyclic triazole and pyrazole lactams as allosteric modulators of mglur5 receptors |
| GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| MX2014000648A (es) | 2011-07-19 | 2014-09-25 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y sus usos. |
| AU2012284088B2 (en) | 2011-07-19 | 2015-10-08 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| KR20140088887A (ko) * | 2011-11-03 | 2014-07-11 | 머크 샤프 앤드 돔 코포레이션 | mGluR2-음성 알로스테릭 조절제로서의 퀴놀린 카르복스아미드 및 퀴놀린 카르보니트릴 유도체, 조성물, 및 그의 용도 |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US20130281397A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| EP2666775A1 (en) * | 2012-05-21 | 2013-11-27 | Domain Therapeutics | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors |
| US20130345205A1 (en) * | 2012-06-20 | 2013-12-26 | Vanderbilt University | Substituted bicyclic aralkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors |
| KR20150023822A (ko) * | 2012-06-20 | 2015-03-05 | 벤더르빌트 유니버시티 | Mglur5 수용체의 알로스테릭 조절물질로서 치환된 바이사이클릭 알콕시 피라졸 유사체 |
| RU2015116749A (ru) | 2012-10-23 | 2016-12-20 | Ф. Хоффманн-Ля Рош Аг | Антагонисты mglu2/3 для лечения аутических расстройств |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| FR3024461B1 (fr) | 2014-07-31 | 2017-12-29 | Total Marketing Services | Compositions lubrifiantes pour vehicule a moteur |
| JO3601B1 (ar) | 2014-08-01 | 2020-07-05 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| JOP20150179B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| JP6517340B2 (ja) * | 2014-08-01 | 2019-05-22 | ヤンセン ファーマシューティカ エヌ．ベー． | ６，７−ジヒドロピラゾロ［１，５−ａ］ピラジン−４（５Ｈ）−オン化合物およびＭＧＬＵＲ２受容体の負のアロステリック調節因子としてのそれらの使用 |
| RU2696135C2 (ru) | 2014-08-01 | 2019-07-31 | Янссен Фармацевтика Нв | 6,7-ДИГИДРОПИРАЗОЛО[1,5-α]ПИРАЗИН-4(5Н)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2 |
| JOP20150177B1 (ar) * | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| CN107001375B (zh) | 2014-12-03 | 2020-06-09 | 詹森药业有限公司 | 6,7-二氢吡唑并[1,5-a]吡嗪-4(5H)-酮化合物及其作为MGLUR2受体的负向别构调节剂的用途 |
| JP6861154B2 (ja) | 2014-12-03 | 2021-04-21 | ヤンセン ファーマシューティカ エヌ．ベー． | 放射標識されたｍＧｌｕＲ２ ＰＥＴリガンド |
| HUE050665T2 (hu) | 2015-12-18 | 2020-12-28 | Janssen Pharmaceutica Nv | Radiojelzett MGLUR2/3 PET ligandumok |
| US11045562B2 (en) | 2015-12-18 | 2021-06-29 | Janssen Pharmaceutica Nv | Radiolabelled mGluR2/3 PET ligands |
-
2015
- 2015-12-02 CN CN201580065918.7A patent/CN107001375B/zh not_active Expired - Fee Related
- 2015-12-02 WO PCT/EP2015/078285 patent/WO2016087487A1/en not_active Ceased
- 2015-12-02 CA CA2967153A patent/CA2967153A1/en active Pending
- 2015-12-02 US US15/533,308 patent/US10072014B2/en active Active
- 2015-12-02 AU AU2015357167A patent/AU2015357167B2/en not_active Ceased
- 2015-12-02 RU RU2017123038A patent/RU2711382C2/ru active
- 2015-12-02 ES ES15802148T patent/ES2727379T3/es active Active
- 2015-12-02 EP EP15802148.5A patent/EP3227295B1/en active Active
- 2015-12-02 JP JP2017529629A patent/JP6689856B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536399A5 (enExample) | ||
| AU2019283921B2 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
| JP5406039B2 (ja) | タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体 | |
| KR102588955B1 (ko) | 이환식 화합물 및 암의 치료에서의 이의 용도 | |
| JP5380447B2 (ja) | 増殖性疾患の処置のための、ヒトタンパク質キナーゼｐｌｋ１ないしｐｌｋ４の阻害剤としての４−（９−（３，３−ジフルオロシクロペンチル）−５，７，７−トリメチル−６−オキソ−６，７，８，９−テトラヒドロ−５ｈ−ピリミド［４，５−ｂ［１，４］ジアゼパン−２−イルアミノ］−３−メトキシベンザミド誘導体 | |
| EP3190889B1 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
| JP2020196726A (ja) | Ｃｄｋ阻害剤としての置換型ヘテロシクリル誘導体 | |
| JP6927589B2 (ja) | 哺乳類ヒストンデアセチラーゼ活性の阻害剤として有用な二環式ヒドロキサム酸 | |
| KR100742014B1 (ko) | Ｇａｂａ계 조절제 | |
| AU2017376398B2 (en) | Aminopyrazoles as selective janus kinase inhibitors | |
| CA2773742C (en) | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors | |
| JP6800885B2 (ja) | イミダゾピラジン及びピラゾロピリミジン、並びにａｍｐａ受容体調節物質としてのこれらの使用 | |
| KR20060120393A (ko) | 글리코겐 신타아제 키나제 3 저해제로서의트리아졸로피리미딘 유도체 | |
| JP2020503374A (ja) | Ｂｃｌ６阻害剤としての新規の６−アミノキノリノン化合物および誘導体 | |
| EP2488520A1 (en) | Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor | |
| JP7088965B2 (ja) | アリール複素環ピペリジノンホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト | |
| CA2781891A1 (en) | Novel tricyclic compounds as protein kinase inhibitors | |
| JP2020504747A (ja) | ベンズイミダゾール誘導体、調製方法およびそれらの使用 | |
| KR20100138991A (ko) | 1-헤테로사이클릴-1,5-디하이드로-피라졸로[3,4-ｄ]피리미딘-4-온 유도체 및 ｐｄｅ９ａ 조절인자로서의 이의 용도 | |
| JP2007537253A (ja) | ３環式および２環式ヘテロアリールヒスタミン３受容体リガンド | |
| KR20170066417A (ko) | Pde1 억제제로서의 트리아졸로피라지논 | |
| WO2014151784A1 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| KR20240164495A (ko) | Nlrp3의 억제제 | |
| Ishida et al. | Synthetic study of perophoramidine: construction of pentacyclic core structure via SmI2-mediated reductive cyclization | |
| EP3544980B1 (en) | Gsk-3 inhibitors |